What treatments can be administered to raise a serum albumin concentration of 1.8 g/dL?

Treatment for Serum Albumin of 1.8 g/dL

The approach to raising a serum albumin of 1.8 g/dL depends entirely on the underlying cause: in cirrhosis with specific complications (spontaneous bacterial peritonitis, hepatorenal syndrome, or large-volume paracentesis), intravenous albumin is indicated and improves mortality; in hemodialysis patients, oral nutrition supplements or intradialytic parenteral nutrition should be used; for other causes of hypoalbuminemia, treating the underlying condition is paramount as IV albumin does not improve outcomes.

Clinical Context Determines Treatment

The critical first step is identifying why albumin is low, as this dictates whether albumin infusion is beneficial or potentially harmful:

For Cirrhosis Patients - IV Albumin Has Proven Benefit in Specific Scenarios:

Use IV albumin in these three situations 1:

• Spontaneous bacterial peritonitis (SBP): Albumin plus antibiotics reduces kidney impairment (OR 0.21) and mortality (OR 0.34) compared to antibiotics alone. One trial showed mortality reduction from 29% to 10% (p=0.01)

• Hepatorenal syndrome (HRS): Combine albumin with terlipressin (1 mg IV every 6 hours, can increase to 2 mg if insufficient response) 2. This is FDA-approved and does not require ICU monitoring

• Large-volume paracentesis: Albumin prevents post-paracentesis circulatory dysfunction

• Hepatic encephalopathy: Albumin (1.5 g/kg/day for up to 10 days) plus lactulose showed 75% complete resolution vs 53% with lactulose alone, and reduced mortality from 32% to 18% at day 10 1

Do NOT use routine IV albumin for:

• General hypoalbuminemia in cirrhosis without the above complications - the ATTIRE trial (N=777) targeting albumin >30 g/L showed no benefit and increased serious adverse events, primarily pulmonary edema 1
• Cirrhosis with sepsis from extraperitoneal infections - no mortality benefit and 5-fold increased risk of pulmonary edema (OR 5.17) 1

For Hemodialysis Patients - Use Nutritional Supplementation:

Oral nutrition supplements (ONS) or intradialytic parenteral nutrition (IDPN) significantly improve albumin 3. The standardized mean difference was 0.372 g/dL (p=0.007) in a 2026 meta-analysis.

More specifically, protein-enriched snacks during dialysis (28.7 g protein vs standard 8.8 g) increased albumin from 3.43 to 3.69 g/dL over 16 months 4. This simple intervention works regardless of baseline albumin level.

For Other Causes of Hypoalbuminemia:

IV albumin does NOT improve outcomes in general hypoalbuminemic patients. A randomized trial in patients receiving total parenteral nutrition showed that 25 g/day IV albumin increased serum levels but did not reduce morbidity or mortality 5. Albumin metabolism rates were extremely high (17-20 g/day), indicating rapid catabolism in catabolic states.

Focus on treating the underlying cause:

• Nephrotic syndrome: Treat the kidney disease
• Malnutrition: Nutritional support
• Inflammatory states: Address the inflammation
• Protein-losing enteropathy: Treat GI condition

Dosing When IV Albumin Is Indicated

For cirrhosis patients with appropriate indications 1, 6:

• Target serum albumin ≥30 g/L
• Typical dosing: 1.5 g/kg on day 1, then 1.0 g/kg on day 3
• For SBP: 1.5 g/kg within 6 hours of diagnosis, then 1.0 g/kg on day 3
• For large-volume paracentesis: 8 g per liter of ascites removed
• Duration: Up to 14 days depending on indication

Critical Pitfalls to Avoid

Volume overload is the major risk 1, 2:

• Patients with ACLF grade 3 are at highest risk of respiratory failure
• Monitor oxygen saturation - do not give if SpO2 <90%
• In the CONFIRM trial, respiratory failure occurred in 14% vs 5% with placebo
• Use judicious albumin dosing, especially before terlipressin therapy

Contraindications for terlipressin + albumin 2:

• Active coronary, peripheral, or mesenteric ischemia
• Serum creatinine >5 mg/dL (unlikely to benefit)
• MELD score ≥35 (risks may outweigh benefits)

Do not use albumin as a general "nutritional" intervention - it does not address the underlying synthetic defect and has high metabolic turnover rates (17-20 g/day) in catabolic states 5.